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Abstract
Background: Treatment paradigms for atrial fibrillation (AF) are highly variable. This study 
explores the management practices for AF between general cardiologists and electrophysiolo-
gists in an academic institution.
Methods: One hundred and eighty eight patients with AF who had primary outpatient evaluation 
by either a cardiologist (n = 94) or electrophysiologist (n = 94) in 2008 were selected from the 
North western electronic medical record and included in the study. Chart review was used to deter-
mine the type of therapy, methods of monitoring AF, antiarrhythmic drug use patterns and outcome.
Results: Patients seen by cardiologists vs. electrophysiologists were older (70.3 ± 11.8 vs. 
65.3 ± 10.3, p = 0.002) and had more diabetes (21.3% vs. 10.6%, p = 0.046), renal disease 
(29.0% vs. 9.2%, p = 0.001) and coronary artery disease (40.4% vs. 23.4%, p = 0.01).  
A rate control strategy was used more often (80.9% vs. 54.3%, p < 0.001), and antiarrhythmics 
were prescribed less (10.6% vs. 31.9%, p < 0.001) by cardiologists than electrophysiologists. 
Antiarrhythmic choices were amiodarone (33.3%), sotalol (20.0%), flecainide (13.3%), propa-
fenone (13.3%), and dofetilide (23.3%) for electrophysiologists, and were limited to amiodarone 
(80%) and sotalol (20%) for cardiologists. After a mean follow-up of 14.0 ± 11.6 and 12.8 ± 
± 11.1 months (p = 0.44) for patients managed by cardiologists and electrophysiologists, mor-
tality was 13.8% and 6.4% (p = 0.09), respectively. Long-term ambulatory electrocardiogram 
monitoring was used more frequently by electrophysiologists (74.4%) than by cardiologists 
(55.6%, p = 0.15).
Conclusions: Practice patterns for treatment of AF significantly differ between electrophy-
siologists and cardiologists. Understanding specialist treatment patterns will help optimize 
individualized therapy for treatment of AF. (Cardiol J 2014; 21, 3: 293–298)
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Introduction
Atrial fibrillation (AF) is the most common 
sustained cardiac arrhythmia with a prevalence of 
approximately 1–2% affecting up to 9% of adults 
older than 80 years [1]. AF is associated with 
significant morbidity and mortality [2]. There is 
a 5-fold increase in the risk of stroke [3], a decline 
in quality of life [4–6] and functional status [7–10]. 
The rate of AF-related hospitalizations is projected 
to rise 2–3 fold in the coming years [11].
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The 2 general approaches to the management 
of AF involve rate or rhythm control. Rate control 
focuses on controlling the ventricular response 
rate with atrioventricular nodal blocking agents 
and the concurrent use of anticoagulation, if indi-
cated. Rhythm control is aimed at restoring and 
maintaining sinus rhythm using a plethora of 
options such as antiarrhythmic drugs and non-
-pharmacological approaches [12, 13].
Various studies have attempted to define 
optimal strategies for the management of AF. The 
AFFIRM study showed that rhythm control was 
not superior to rate control in terms of overall 
mortality, stroke and quality of life [14]. Although 
these findings were replicated in other studies 
[15–21], guidelines incorporate both approaches, 
which can be individualized based on variables 
such as age, symptoms, underlying cardiac abnor-
malities, medical co-morbidities and the type of 
AF (paroxysmal, persistent or chronic). The many 
options offered by these guidelines lead to varying 
treatment styles, which are based on physician 
training, experience, patient preference and even 
misconceptions [12, 13, 22].
This study explores the management pra-
ctices for AF between general cardiologists and 
electrophysiologists in an academic institution. 
We postulated that there would be greater efforts 
at rhythm control among the electrophysiologists. 
Methods
Study design
Using 2008 as the index year, we attempted to 
indentify 100 patients with AF who were treated 
by general cardiologists and 100 patients trea-
ted by electrophysiologists in the Northwestern 
outpatient clinic. Inclusion criteria were age > 40 
years old and objective documentation of AF in the 
medical chart. A total of 236 patients were screened 
from an electronic data warehouse report. Forty-
-eight patients were excluded because only atrial 
flutter was noted or because of lack of objective 
documentation of AF. 
Each chart was reviewed for demographic data 
and prior history of hypertension, stroke, diabetes 
mellitus, myocardial infarction, coronary artery 
disease, congestive heart failure and renal disease. 
Echocardiogram reports were reviewed for evi-
dence of left atrial enlargement, left ventricular 
hypertrophy, aortic or mitral valve disease and 
left ventricular ejection fraction. Valvular disease 
(aortic insufficiency, aortic regurgitation, mitral 
stenosis or mitral regurgitation) was considered 
significant if it was reported to be moderate or 
severe on echocardiogram reports. Renal disease 
was considered present if the recorded glomerular 
filtration rate was < 60 mL/min.
The type of AF was classified as paroxysmal: 
self-terminating episodes of AF for up to 7 days; 
persistent: AF lasting more than 7 days and usually 
requiring some kind of antiarrhythmic therapy to 
restore sinus rhythm; and permanent: persistent 
AF lasting more than 1 year or failure to restore 
sinus rhythm despite multiple antiarrhythmic 
therapies. 
Specific treatment parameters that were col-
lected include referral source, type of therapy, 
specific antiarrhythmic drugs prescribed by the 
treating physician at the index visit and methods 
of monitoring AF. Follow-up information collected 
included absence of AF, use of catheter abla-
tion, last documented rhythm, all-cause mortality, 
stroke/transient ischemic attack, and AF-related 
hospitalization.
Last documented rhythm is the rhythm recor-
ded at the last office visit or last electrocardiogram 
(ECG). Methods of monitoring AF were grouped 
into 2 categories, ECG and long term monito-
ring. The latter includes 24-h Holter monitoring, 
event monitoring, and implantable devices that 
monitor AF.
Information on mortality was obtained from 
the social security death index. AF related hospi-
talizations included admissions for drug loading, 
cardioversion, or AF with rapid ventricular re-
sponse rate.
The study was approved by the Northwestern 
University Institutional Review Board.
Data analysis
Categorical variables are expressed as absolu-
te numbers and percentages; quantitative variables 
are expressed as mean ± standard deviation (SD). 
Proportions were compared using 2-proportion 
Z-test and continuous variables compared using 
T-test. A p < 0.05 was considered significant.
Results
There were 94 patients managed by cardiolo-
gists and 94 patients managed by electrophysio-
logists with a mean follow-up duration of 14.0 ± 
± 11.6 and 12.8 ± 11.1 months, respectively. Table 1 
shows the patient characteristics. The patients 
seen by the general cardiologists were older com-
pared to those seen by the electrophysiologists 
(70.0 ± 11.8 vs. 65.3 ± 10.3 years, p = 0.002). 
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There was no significant difference in hyperten-
sion, prior stroke, or prior myocardial infarction 
between the two groups. Diabetes mellitus (21.3% 
vs. 10.6%, p = 0.046), renal disease (29.0% vs. 
9.2%, p = 0.001), coronary artery disease (40.4% 
vs. 23.4%, p = 0.01) and coronary artery bypass 
surgery (17.0% vs. 6.4%, p = 0.02) were more 
common in the patients seen by cardiologists vs. 
electrophysiologists. More patients seen by car-
diologists had been on amiodarone (19% vs. 6%, 
p = 0.005) prior to the index visit compared to 
electrophysiologists. Only 3 patients seen by elec-
trophysiologists had had prior catheter ablations. 
Referral sources to electrophysiologists 
were from “Cardiologists” (17%), “Primary care 
provider” (79.8%), “Self referrals” (2.1%) and 
“Cardiothoracic surgeon” (1.1%). In comparison, 
referral sources to cardiologists were 3.2%, 73.4%, 
9.6% and 13.8%, respectively.
The type of AF varied between the two groups. 
While there was no significant difference in the 
proportion of patients with paroxysmal AF (55.3% 
vs. 60.6%, p = 0.46), there were more patients 
with persistent AF seen by electrophysiologists 
(31.9% vs. 13.8%, p = 0.003) and fewer patients 
with permanent AF (12.8% vs. 25.5%, p = 0.03). 
The median CHADS2 score was 2 for patients 
seen by cardiologists vs. 1 for patients seen by 
electrophysiologists.
Treatment parameters
Cardiologists employed a rate control strategy 
more often (80.9% vs. 54.3%, p < 0.001) than 
electrophysiologists. Consequently, antiarrhythmic 
drugs were prescribed less often (10.6% vs. 31.9%, 
p < 0.001). Cardiologists used fewer antiarrhythmic 
drugs (amiodarone: 80% and sotalol: 20%) vs. the 
broader array of antiarrhythmic drugs (amiodarone: 
Table 1. Patient characteristics based on whether the patient was treated by a cardiologist or electro­
physiologist.
Characteristics Cardiologist (n = 94) Electrophysiologist (n = 94) P
Male 50 (53.2%) 68 (72.3%) 0.007
White 65 (69.2%) 77 (81.9%) 0.04
Age [years] 70.3 ± 11.8 65.3 ± 10.3 0.002
Body mass index [kg/m2] 28.7 ± 7.4 29.9 ± 6.0 0.25
Active smoker 3 (3.2%) 3 (3.2%) 0.70
Hypertension 61 (64.9%) 53 (56.4%) 0.23
Diabetes mellitus 20 (21.3%) 10 (10.6%) 0.046
Hypercholesterolemia 59 (62.8%) 55 (58.5%) 0.55
Renal disease 27 (29.0%) 8 (9.2%) 0.001
History of stroke 9 (9.6%) 5 (5.3%) 0.27
Previous myocardial infarction 3 (3.2%) 3 (3.2%) 1.00
Coronary artery disease 38 (40.4%) 22 (23.4%) 0.01
Coronary artery bypass graft surgery 16 (17.0%) 6 (6.4%) 0.02
Congestive heart failure 11 (11.7%) 9 (9.6%) 0.64
Percutaneous coronary intervention 11 (11.7%) 7 (7.5%) 0.32
Left ventricular ejection fraction [%] 57.5 ± 8.8 55.7 ± 8.6 0.16
Left atrial enlargement 38 (41.3%) 27 (30.7%) 0.14
Valvular disease 46 (49.5%) 34 (38.6%) 0.14
Valve repair 16 (17.0%) 4 (4.3%) 0.008
Prior antiarrhythmic use: 21 (22.3%) 20 (21.3%) 0.86
Amiodarone 19 (20.2%) 6 (6.4%) 0.005
Sotalol 2 (2.1%) 6 (4%)
Flecainide 0 (0%) 2 (2.1%)
Propafenone 0 (0%) 8 (8.5%)
Dofetilide 0 (0%) 1 (1.1%)
Prior intervention: 10 (10.6%) 16 (17.0%) 0.20
Direct current cardioversion 8 (8.5%) 13 (13.8%) 0.25
Catheter ablation 0 (0%) 3 (3.2%)
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33.3%, sotalol: 20%, flecainide: 13.3%, propafeno-
ne: 13.3%, and dofetilide: 23.3%) used by electro-
physiologists (Table 2).
Of the 18 and 43 patients treated by cardio-
logists and electrophysiologists with a rhythm 
control strategy, the last documented rhythm was 
sinus in 83.3% and 83.7%, respectively. In these 
patients, long-term monitoring was used less by 
cardiologists (55.6% vs. 74.4%, p = 0.15) (Table 3). 
However, AF was detected in follow-up, among 
those treated with a rhythm control strategy, in 
27.8% of patients treated by cardiologists and 
65.1% of those treated by electrophysiologists 
(p = 0.008). Catheter ablation was used less 
(0% vs. 11.6%, p = 0.13) among cardiologists than 
among electrophysiologists.
Of the patients treated with a rate control 
strategy, long-term monitoring was used less by 
cardiologists (n = 76) compared to electrophysio-
logists (n = 51) (34.2% vs. 64.7%, p = 0.0007), 
respectively (Table 3).
At the last follow-up visit, more patients 
treated by cardiologists were treated with a rate 
control strategy (91.5% vs. 60.6%, p < 0.001) than 
at the index visit.
AF-related hospitalization did not differ be-
tween patients managed by cardiologists vs. elec-
trophysiologists (38.3% vs. 40.4%, p = 0.88). All 
cause mortality was 13.8% among patients treated 
by cardiologists compared to 6.4% among patients 
treated by electrophysiologists (p = 0.09).
Discussion
This study shows significantly different practi-
ce patterns for treatment of AF between general 
cardiologists and electrophysiologists in a single 
academic practice. The most notable differences 
between the two groups are in treatment strategy, 
array of antiarrhythmic drugs used for treatment, 
and type of monitoring used. As this is not a ran-
domized study and patient characteristics clearly 
differed between the two groups, it is not possible 
to make conclusions regarding outcomes, except 
to note that major differences were not observed. 
Importantly, these data represent practice patterns 
at this institution, and may not be representative of 
other institutions. As there is no dominant strategy 
for the treatment of AF, delineating these practice 
patterns can provide an important window into the 
Table 3. Use of long­term monitoring by cardiologists and electrophysiologists.
Cardiologist Electrophysiologist P
Rhythm control n = 18 n = 43
Long term monitoring: 10 (55.6%) 32 (74.4%) 0.15
Holter monitor 6 (33.3%) 17 (39.5%) 0.65
Event monitor 6 (33.3%) 20 (46.5%) 0.34
Implantable device 0 (0%) 1 (2.3%) 0.51
Rate control n = 76 n = 51
Long term monitoring: 26 (34.2%) 33 (64.7%) 0.0007
Holter monitor 19 (25.0%) 25 (49.0%) 0.005
Event monitor 7 (9.2%) 12 (23.5%) 0.027
Implantable device 0 (0%) 2 (3.9%) 0.082
Table 2. Type of management.
  Cardiologist (n = 94) Electrophysiologist (n = 94) P
Rate control 76 (80.9%) 51 (54.3%) < 0.001
Anti­arrhythmic: 10 (10.6%) 30 (31.9%) < 0.001
Amiodarone 8 (80.0%) 10 (33.3%)
Sotalol 2 (20.0%) 6 (20.0%)
Flecainide 0 (0%) 4 (13.3%)
Propafenone 0 (0%) 4 (13.3%)
Dofetilide 0 (0%) 7 (23.3%)
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translation of medical information into practice pat-
terns and could help set expectations for patients, 
referring doctors, and health care systems on what 
therapies each type of physician may offer. 
Rate and rhythm control are both acceptable 
strategies for the treatment for AF. The most 
recent guidelines [12, 13] recommend an indivi-
dualized approach to treatment based on variables 
such as patient’s age, degree and frequency of 
symptoms, activity level and other cardiovascular 
comorbidities. It suggests that rate control may be 
appropriate in older patients with minor symptoms, 
while rhythm control can be used in patients with 
symptoms despite adequate rate control, and in 
young patients in whom catheter ablation may be 
an option. Indeed, in the present study, the patients 
seen by electrophysiologists were younger, with 
less cardiovascular comorbidity, perhaps explaining 
the greater use of rhythm control by electrophy-
siologists compared to cardiologists. While rhythm 
control may benefit patients with symptomatic AF, 
on a population basis, it does not improve survival 
[14–17, 21] nor quality of life [14, 16, 18, 21, 23] 
compared to rate control, highlighting the impor-
tance of individualizing therapy as indicated in the 
guidelines [13].
Notably, even among patients treated with 
a rhythm control strategy, the electrophysiologists 
used a broader array of antiarrhythmic drugs. This 
may reflect increased familiarity or comfort with 
antiarrhythmic drugs among electrophysiologists. 
Additionally, there are barriers to prescription of 
some antiarrhythmic drugs, such as dofetilide, which 
requires approval training prior to prescription.
Monitoring for AF during follow-up depends 
greatly on the goal of therapy [12, 13]. If the goal 
is to restore sinus rhythm, then more intense mo-
nitoring with long-term monitoring is appropriate 
[24–26]. On the other hand, if the goal is symptom 
control, less intensive monitoring may be ade-
quate [24, 27]. Our study showed more intensive 
monitoring by electrophysiologists compared to 
cardiologists in patients treated with a rate control 
strategy. This practice may be useful for assessing 
the burden of AF in asymptomatic patients [24], 
guide ventricular rate control, anticoagulation 
therapy and to guide further decisions to cross 
over to a rhythm control strategy [28]. Intensive 
monitoring will affect the number of patients with 
documented AF during follow-up [24–28]. Further - 
more, increased use of amiodarone, which is 
a moderately effective antiarrhythmic drug [29, 30], 
by cardiologists may have contributed to the lower 
proportion of documented AF on follow-up.
Limitations of the study
The major limitation of this study is that it 
reflects the practice patterns at one institution and 
cannot necessarily be generalized to other practi-
ces. Furthermore, it is a small, non-randomized 
study with potential referral bias based on different 
patient characteristics between the two groups. 
Conclusions
In summary, physicians who are performing 
primary evaluations of patients with AF need to 
formulate a general treatment approach to AF 
individualized to their patient, understand the 
practice patterns of the physicians to whom they 
refer patients, and make informed decisions about 
which type of specialist may be most appropriate 
for their patient. 
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